4-[1-(2-aminopyrimidin-4-yl)-2-[(2-methoxyethyl)amino]-1H-1,3-benzodiazol-6-yl]-2-methylbut-3-yn-2-ol | 1394121-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-[1-(2-aminopyrimidin-4-yl)-2-[(2-methoxyethyl)amino]-1H-1,3-benzodiazol-6-yl]-2-methylbut-3-yn-2-ol
• 英文别名: 4-[3-(2-aminopyrimidin-4-yl)-2-(2-methoxyethylamino)benzimidazol-5-yl]-2-methylbut-3-yn-2-ol
• CAS: 1394121-09-5
• 化学式: C₁₉H₂₂N₆O₂
• 分子量: 366.423
• InChiKey: ZGLIZEYZNJYHGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氟-4-溴硝基苯 在 bis-triphenylphosphine-palladium(II) chloride 、 tin(ll) chloride ammonium hydroxide 、 sodium hydride 、 caesium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二甲基亚砜 、 异丙醇 、 2-甲氧基乙胺 为溶剂， 反应 96.17h， 生成 4-[1-(2-aminopyrimidin-4-yl)-2-[(2-methoxyethyl)amino]-1H-1,3-benzodiazol-6-yl]-2-methylbut-3-yn-2-ol
  参考文献：
  名称：

  6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR

  摘要：

  这项发明涉及公式I的新化合物： 其中A、Y、R1、R2和下标b各自具有如本文所述的含义，以及公式I的化合物、立体异构体、几何异构体、互变异构体、溶剂合物、代谢物、同位素、药学上可接受的盐或其前药。公式I的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度激活的疾病和紊乱中是有用的。

  公开号：

  US20120214762A1

文献信息

• 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor
  申请人：Genentech, Inc.

  公开号：US20150038460A1

  公开（公告）日：2015-02-05

  The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  该发明涉及公式I的新化合物：其中A，Y，R1，R2和下标b各自具有如下所述的含义，以及公式I的化合物，立体异构体，几何异构体，互变异构体，溶剂化物，代谢物，同位素，药学上可接受的盐或其前药。公式I的化合物及其制药组合物在治疗疾病和障碍方面有用，其中观察到NF-kB信号不良或过度激活。
• 6,5-heterocyclic propargylic alcohol compounds and uses therefor
  申请人：Staben Steven

  公开号：US08901313B2

  公开（公告）日：2014-12-02

  The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及一种新型化合物I的公式：其中A，Y，R1，R2和下标b具有如下所述的含义，以及化合物I的立体异构体，几何异构体，互变异构体，溶剂化物，代谢物，同位素，药学上可接受的盐或其前药。公式I化合物及其制药组合物在治疗疾病和障碍方面有用，其中观察到NF-kB信号的不良或过度激活。
• Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors
  作者：Steven T. Staben、Jianwen A. Feng、Karen Lyle、Marcia Belvin、Jason Boggs、Jason D. Burch、Ching-ching Chua、Haifeng Cui、Antonio G. DiPasquale、Lori S. Friedman、Christopher Heise、Hartmut Koeppen、Adrian Kotey、Robert Mintzer、Angela Oh、David Allen Roberts、Lionel Rouge、Joachim Rudolph、Christine Tam、Weiru Wang、Yisong Xiao、Amy Young、Yamin Zhang、Klaus P. Hoeflich

  DOI：10.1021/jm401768t

  日期：2014.2.13

  Structure-based methods were used to design a potent and highly selective group II p21-activated kinase (PAK) inhibitor with a novel binding mode, compound 17. Hydrophobic interactions within a lipophilic pocket past the methionine gatekeeper of group II PAKs approached by these type I 1/2 binders were found to be important for improving potency. A structure-based hypothesis and strategy for achieving selectivity over group I PAKs, and the broad kinome, based on unique flexibility of this lipophilic pocket, is presented. A concentration-dependent decrease in tumor cell migration and invasion in two triple-negative breast cancer cell lines was observed with compound 17.
• US8901313B2
  申请人：——

  公开号：US8901313B2

  公开（公告）日：2014-12-02
• [EN] 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR<br/>[FR] COMPOSÉS D'ALCOOL PROPARGYLIQUE 6,5-HÉTÉROCYCLIQUES ET UTILISATIONS DE CEUX-CI
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012123522A1

  公开（公告）日：2012-09-20

  The invention relates to novel compounds of Formula (I) wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.